Latent tuberculosis infection

This early-stage study tests a new vaccine called Ad5-105K to see if it is safe and triggers an immune response against tuberculosis (TB). About 36 healthy adults aged 18 to 49 who have been exposed to TB bacteria (but have no active disease) will receive either the vaccine or a …

This study tests a digital package called CARE-TB to help people with tuberculosis take their medication as prescribed. The package includes video observation of pill-taking, digital reminders, telecounselling, and educational materials. Researchers will compare this approach to …

This study tests a 1-month course of three medicines (isoniazid, rifapentine, and vitamin B6) to treat latent tuberculosis in 25 adults with end-stage kidney disease who are candidates for a kidney transplant. The goal is to see if this shorter treatment is safe and easy to compl…

This study is testing two tuberculosis (TB) prevention treatments in pregnant women who also have HIV. The goal is to see if these treatments are safe and how they interact with the HIV medication dolutegravir. About 252 pregnant women will take either a daily TB drug for one mon…

This study tests whether a once-weekly combination of two drugs (rifapentine and isoniazid) can safely prevent tuberculosis in children and teens with HIV who are already taking the antiretroviral dolutegravir. About 92 participants aged 3 months to 17 years will receive the TB p…

This study tests whether two new 17-week drug combinations can treat pulmonary tuberculosis as effectively as the standard 6-month regimen. About 288 people with TB will receive one of three daily pill regimens. The goal is to see if shorter treatment can clear the infection fast…

This project tests an integrated approach to lung health in Zambia. Community and primary care clinics screen people with cough, breathlessness or other respiratory symptoms for TB, post-TB lung disease, COPD, silicosis and pneumonia. All participants get a symptom check and a di…

This study evaluates a new blood test that aims to directly detect the bacteria causing dormant tuberculosis (TB), rather than relying on the body's immune response. Current tests cannot tell if treatment worked or who will develop active TB, leading to unnecessary antibiotics. R…

Researchers are testing whether a 4-week daily course of isoniazid and rifapentine can prevent active tuberculosis as well as the standard 12-week weekly course in people with HIV who have latent TB infection. The trial enrolls about 2,500 adults in a high TB burden country. Both…

Tuberculosis infection can progress to active, contagious TB disease, but preventive treatment often lasts three to nine months and many people do not finish it. This Phase 3 trial in Hanoi, Vietnam, compares a new one-month regimen of daily isoniazid and rifapentine with the sta…

This study looks at better ways to find and prevent tuberculosis (TB) in people living with HIV. Researchers will test a new screening method and offer patients a choice of TB preventive medicines with extra support like text reminders. The goal is to improve TB detection and hel…

This study tests whether taking two TB prevention drugs daily for one month works as well as taking them weekly for three months. It includes 1,000 people with HIV or those living with someone recently diagnosed with TB. The goal is to see which schedule more people complete and …

This study investigates whether taking rifampicin for latent tuberculosis increases the risk of antibiotic resistance in Staphylococcus aureus bacteria that naturally live on the skin. Researchers will compare people treated with rifampicin to those treated with isoniazid, taking…

This study investigates whether a blood test can detect the bacteria that cause tuberculosis (TB) in people with active TB and their asymptomatic household contacts. Researchers in Uganda will use several methods, including a DNA-based test, to look for TB bacteria in blood sampl…

This study looks back at the medical records of 150 children treated for tuberculosis at a French hospital. The goal is to see how many were cured, how many had problems, and why some treatments failed. By understanding these patterns, doctors hope to improve care for children wi…